| File | File Last Modified | Page | Page Last Modified |
| 03001_CR4_Grasela_Ted_V1.pdf |
Wed, Apr 7, 2004 - 16:05 EDT |
Practical Approaches to Utilizing Exposure-Response Relationships to Inform Drug Development and Prescribing Decision-Making |
Mon, Jan 21, 2008 - 14:05 EST |
| 1996_aaps_luann_pnu.pdf |
Tue, Jan 11, 2005 - 12:42 EST |
Implementation of Concentration Dependent 'First-Pass' Models using NONMEM |
Thu, Mar 6, 2008 - 11:07 EST |
| 2004.AAPS.Cirincione.Roundtable.pdf |
Thu, Dec 16, 2004 - 07:41 EST |
An Historical Review of the Incorporation of UGT 1A1 Genotype in Population of UGT 1A1 Genotype in Population Analyses of Atazanav |
Mon, Jan 21, 2008 - 14:05 EST |
| 2276_tgc_poppkph2_icaac_v4_2005dec09.pdf |
Wed, Jan 4, 2006 - 09:28 EST |
Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-abdominal or Skin and Skin-Structure Infections |
Mon, Jan 21, 2008 - 14:05 EST |
| 2276_tgc_ppkph3_aaps_v4_2005oct31_sent.pdf |
Wed, Jan 4, 2006 - 09:05 EST |
Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-abdominal or Skin and Skin-Structure Infections |
Mon, Jan 21, 2008 - 14:05 EST |
| 3021_AAPS.pdf |
Tue, May 27, 2003 - 10:32 EDT |
Lack of Significant Drug Interactions for Sumanirole in Phase II Studies Using Population Pharmacokinetic (PPK) Methods |
Mon, Jan 21, 2008 - 14:04 EST |
| 3022_AAPS.pdf |
Tue, May 27, 2003 - 10:32 EDT |
Evaluation of the Relationship Between Sumanirole Exposure and Orthostatic Hypotension |
Mon, Jan 21, 2008 - 14:04 EST |
| AAPS2002poster_v6.2002oct29.pdf |
Fri, May 6, 2005 - 10:32 EDT |
Evaluation of Covariate Effects on Population Pharmacokinetics (PPK) of Both Parent Drug and Metabolite(s) from Clinical Trial Data without Metabolite Administration or Excretion Sampling |
Mon, Jan 21, 2008 - 14:04 EST |
| AAPS2004-ORI-HepaticImp-Poster.2004oct27.pdf |
Mon, Nov 1, 2004 - 16:07 EST |
Effect of Hepatic Impairment on the Pharmacokinetics of the Novel Glycopeptide Oritavancin |
Mon, Jan 21, 2008 - 14:05 EST |
| AAPS_2007_poster.pdf |
Wed, Nov 7, 2007 - 09:27 EST |
Influence of Estimation of Inter-Occasion Variability on Detection of Time-Varying Covariates |
Mon, Jan 21, 2008 - 14:05 EST |
| AAPS_202152_xopenex_aaps2006_v3_2006oct24_sent.pdf |
Mon, Nov 6, 2006 - 11:04 EST |
Population Pharmacokinetics of (R)-Albuterol Following Inhaled Levalbuterol or Racemic Albuterol via a Hydrofluoroalkane Metered Dose Inhaler in Pediatric and Adult Asthma Patients |
Mon, Jan 21, 2008 - 14:05 EST |
| aaps_cirincione_2006oct31-1.pdf |
Mon, Nov 6, 2006 - 11:05 EST |
Modeling & Simulation Learn to Speak the Language: Modeling |
Mon, May 5, 2008 - 11:10 EDT |
| AAPS_Owens_Fin_2005.pdf |
Mon, May 15, 2006 - 10:21 EDT |
Population Pharmacokinetics of Modafinil Film-Coated Tablets in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder |
Mon, Jan 21, 2008 - 14:05 EST |
| AAPS_Pediatric_Pop_Grasela_2003Oct27V2.pdf |
Mon, Nov 10, 2003 - 10:35 EST |
The Implementation of Population PK/PD in Pediatric Drug Development |
Mon, Jan 21, 2008 - 14:04 EST |
| AAPS_poster_2004nov01.pdf |
Tue, Nov 2, 2004 - 08:28 EST |
Evaluation of the Bias and Precision of Bayesian Parameter Estimates When Applying a Phase I Model to Sparse Patient Data |
Mon, Jan 21, 2008 - 14:05 EST |
| ACoP_poster_2008feb.pdf |
Mon, Mar 17, 2008 - 10:14 EDT |
Improving the Efficiency and Ensuring the Quality of Data Assembly for Pharmacometric Analysis |
Thu, Oct 16, 2008 - 12:02 EDT |
| Andes_poster.pdf |
Wed, Oct 22, 2003 - 10:02 EDT |
PK- PD Evaluation of Doripenem (DOR) Against Extended Spectrum ß- Lactamase (ESBL) Producing Enterobacteraceae |
Mon, Jan 21, 2008 - 14:05 EST |
| arrest-ascpt2003-poster-2003mar28.pdf |
Tue, May 27, 2003 - 16:57 EDT |
Comparison of Censored Regression (CR) vs. Standard Regression (SR) Analyses for Modeling Relationships Between Minimum Inhibitory Concentrations (MIC) and Patient- and Institution-Specific Variables |
Mon, Jan 21, 2008 - 14:04 EST |
| asa2004.poster.v1.2004sep01-1.pdf |
Mon, Sep 13, 2004 - 09:47 EDT |
Blood Management and Infections in Cardiovascular and Orthopedic Surgery |
Mon, Jan 21, 2008 - 14:05 EST |
| ASCO-2007.pdf |
Wed, Jun 6, 2007 - 11:26 EDT |
Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Hepatoprotective Effect of Dexamethasone on Transient Transaminitis After Trabectedin (ET-743, Yondelis®) Treatment |
Mon, Jan 21, 2008 - 14:05 EST |
| ASCO-pk_poster_final_2005May10.pdf |
Tue, Jun 7, 2005 - 10:49 EDT |
Development of a Pharmacokinetic (PK) Model and Assessment of Patient (PT) Covariate Effects on Dose-Dependent PK following Different Dosing Schedules in Two Phase I Trials of AP23573 (AP), an mTOR Inhabitor |
Mon, Jan 21, 2008 - 14:05 EST |
| ASCO_2004-1.pdf |
Mon, Jun 28, 2004 - 06:57 EDT |
Pharmacogenomic and Pharmacokinetic Assessment of Liposome Encapsulated SN-38 (LE-SN38) in Advanced Cancer Patients |
Mon, Jan 21, 2008 - 14:05 EST |
| ASCPT2003MAR26_Minh.pdf |
Wed, Apr 30, 2003 - 09:57 EDT |
Pharmacokinetic/Pharmacodynamic Analysis of Data from a Phase III Trial of Linezolid IV/PO for the Treatment of Resistant Gram-Positive Bacterial Infections in Children |
Mon, Jan 21, 2008 - 14:04 EST |
| Ascpt2007_amylin_2007mar13.pdf |
Fri, May 4, 2007 - 11:32 EDT |
Effect of Lifestyle Intervention on the Placebo Response in Anti-Obesity Trials: Considerations for Exposure-Response Modeling |
Mon, Jan 21, 2008 - 14:05 EST |
| ASCPT_2007 _FinemanPoster_v4.pdf |
Fri, May 4, 2007 - 11:48 EDT |
Model-Based Evaluations to Select and Confirm Doses in the Clinical Development of Exenatide |
Mon, Jan 21, 2008 - 14:05 EST |
| ascpt_MFA_poster_2008apr02.pdf |
Wed, Apr 23, 2008 - 09:25 EDT |
Model Feasibility Assessment as a Driver for Model Based Drug Development |
Wed, Apr 23, 2008 - 09:27 EDT |
| ascpt_poster_2008mar06.pdf |
Thu, Mar 6, 2008 - 10:10 EST |
Population Pharmacokinetics of Bendamustine and Metabolites in Patients with Indolent Non-Hodgkin Lymphoma |
Wed, Apr 23, 2008 - 14:14 EDT |
| ASCPT_v1_2006mar03.pdf |
Mon, Mar 27, 2006 - 09:14 EST |
Pharmacokinetic/Pharmacodynamic (PK/PD) Model for Tolvaptan in Healthy Subjects |
Mon, Jan 21, 2008 - 14:05 EST |
| ASCPT_v2_2007mar15.pdf |
Tue, May 8, 2007 - 09:12 EDT |
Population Pharmacokinetics of Paliperidone ER in Healthy Subjects and Patients with Schizophrenia |
Tue, Oct 21, 2008 - 13:48 EDT |
| azim.pdf |
Mon, Nov 1, 1999 - 16:29 EST |
Phase III Population Pharmacokinetics and Pharmacodynamics of Azimilide |
Mon, Jan 21, 2008 - 14:04 EST |
| C674.pdf |
Thu, Sep 18, 2003 - 08:37 EDT |
Population Pharmacodynamic Assessment of Atazanavir (BMS-232632) Exposure, Genotype, and Safety |
Mon, Jan 21, 2008 - 14:04 EST |
| cog.eng.posterv2.pdf |
Tue, May 27, 2003 - 09:55 EDT |
Cognitive Engineering - The Tools, Mindset, and Strategy for Integrated Development |
Mon, Jan 21, 2008 - 14:04 EST |
| Cognigen-PK-PD-Final.pdf |
Wed, Sep 17, 2003 - 14:25 EDT |
PK-PD Target Attainment with Monte Carlo Simulation as Decision Support of Phase 2 / 3 Dosing Strategies for the Clinical Development of Doripenem |
Mon, Jan 21, 2008 - 14:05 EST |
| cpt11-poster-2002sep16.pdf |
Wed, Jul 9, 2003 - 13:37 EDT |
Factors Influencing the Pharmacokinetics (PD) of Anticancer Drug Irinotecan (CPT-11) and its Major Metabolites, SN-38 and SN38G |
Mon, Jan 21, 2008 - 14:04 EST |
| CPT11_2002mar19.pdf |
Thu, May 6, 2004 - 18:30 EDT |
Simultaneous Population Pharmacokinetic (PPK) Modeling of Irinotecan (CPT-11) and its Major Metabolites, SN-38 and SN-38G |
Mon, Jan 21, 2008 - 14:04 EST |
| CPT2004i.pdf |
Mon, Apr 19, 2004 - 14:17 EDT |
A Novel Pharmacodynamic Model for Gatifloxacin vs. Salmonella typhi in Timed Kill Curves |
Mon, Jan 21, 2008 - 14:05 EST |
| dia.rtdc.pdf |
Tue, May 27, 2003 - 09:59 EDT |
An Electronic Strategy for Implementing a New Paradigm in Pediatric Drug Development |
Mon, May 5, 2008 - 11:09 EDT |
| DIA_2004June16_Grasela_Ted_V1.pdf |
Mon, Jun 14, 2004 - 09:33 EDT |
The Role of Exposure-Response Evaluations in Global Drug Development |
Mon, Jan 21, 2008 - 14:05 EST |
| DIAposter_97PPTver4.pdf |
Tue, May 27, 2003 - 10:32 EDT |
A New Paradigm of Real-Time Data Assembly to Support Knowledge-Based Decision Making: A Case Study |
Mon, Jan 21, 2008 - 14:04 EST |
| DM06_Cognigen.pdf |
Thu, Jul 24, 2003 - 08:58 EDT |
Rapid Assessment of Dataset Structures |
Mon, Jan 21, 2008 - 14:04 EST |
| dori-poppk-ICAAC2004.pdf |
Thu, Oct 28, 2004 - 14:48 EDT |
Population Pharmacokinetics of Doripenem |
Mon, Jan 21, 2008 - 14:05 EST |
| draft2-AAPS.pdf |
Wed, Oct 29, 2003 - 09:38 EST |
Pharmacokinetic Analysis of Gatifloxacin in Plasma and Sinus Aspirate During Treatment of Acute Maxillary Sinusitis |
Mon, Jan 21, 2008 - 14:04 EST |
| ECCMID-poster-2004apr26.pdf |
Mon, May 10, 2004 - 09:59 EDT |
Use of an in vitro Pharmacodynamic Model & Monte Carlo Simulation to Characterize the Pharmacokinetics and Pharmacodynamics of Gatifloxacin vs Salmonella Typhi |
Mon, Jan 21, 2008 - 14:05 EST |
| ECCMID_2005_cSSSI_ER_poster1.pdf |
Wed, May 11, 2005 - 15:31 EDT |
Exposure-Response Analysis of the Efficaccy of Tigecycline in Patients with complicated skin and skin-structure infected infections |
Mon, Jan 21, 2008 - 14:05 EST |
| ECCMID_2005_cSSSIcohorts_posterP1183-1.pdf |
Wed, May 11, 2005 - 16:32 EDT |
A novel approach for evaluating the microbiological efficacy of Tigecycline in patients with complicated skin and skin-structure infections |
Mon, Jan 21, 2008 - 14:05 EST |
| ECCMID_2005_tigecycline.pdf |
Wed, May 11, 2005 - 15:30 EDT |
Pharmacokinetic/Pharmacodynamic model for the tolerability of Tigecycline in healthy volunteers |
Mon, Jan 21, 2008 - 14:05 EST |
| ECCMID_2006mar24.pdf |
Mon, Mar 27, 2006 - 08:15 EST |
Pharmacokinetic/Pharmacodynamic (PK/PD) Model for the Safety of Tigecycline (T) in Patients with Complicated Intra-Abdominal Infections (cIAI) |
Mon, Jan 21, 2008 - 14:05 EST |
| ECPAG02-Chgpt-model.pdf |
Tue, Jul 8, 2003 - 13:50 EDT |
Change-Point Models: Some Considerations in Implementation |
Mon, Jan 21, 2008 - 14:04 EST |
| ERS_pd_poster_v4_2006aug24.pdf |
Thu, Aug 24, 2006 - 11:23 EDT |
Exposure-Response Relationship for Nebulized Arformoterol in Subjects with COPD |
Mon, Jan 21, 2008 - 14:05 EST |
| ERS_pk_poster_v4_2006aug24.pdf |
Mon, Sep 18, 2006 - 13:47 EDT |
Population Pharmacokinetics of Nebulized Arformoterol in Subjects with COPD |
Mon, Jan 21, 2008 - 14:05 EST |
| Fiedler-Kelly_PopPKPD4mgrs.pdf |
Mon, Nov 10, 2003 - 10:34 EST |
Population PK/PD for Managers: From Identifying and Maximizing the Value-Add to Considerations for Implementation |
Mon, Jan 21, 2008 - 14:04 EST |
| Final_poster2.pdf |
Wed, Apr 30, 2003 - 10:08 EDT |
Population Pharmacokinetics (PK) of Linezolid in Neonates and Young Infants |
Mon, Jan 21, 2008 - 14:04 EST |
| ICAAC2002_Abs_640.pdf |
Tue, Oct 28, 2003 - 13:11 EST |
A Novel Application of Monte Carlo Simulation to Compare PK-PD Target Attainment Rates for Oral Time-Dependent Antimicrobial Regimens |
Mon, Jan 21, 2008 - 14:04 EST |
| ICAAC2003-poster.2003sep10.pdf |
Wed, Sep 17, 2003 - 15:24 EDT |
Characterization of Oritavancin Pharmacokinetics (PK) in Plasma and Blister Fluid in Nornam Healthy Volunteers |
Mon, Jan 21, 2008 - 14:05 EST |
| ICAAC4_ph1_po__PK_Vrs2Reduc_1.pdf |
Thu, Sep 30, 2004 - 09:37 EDT |
Population Pharmacokinetics of Tigecycline in Phase 1 Subjects |
Mon, Jan 21, 2008 - 14:05 EST |
| ICAAC_2001_BMS_232632.pdf |
Thu, Sep 18, 2003 - 08:37 EDT |
Population Pharmacodynamic (PD) Assessment of the Safety and Antiretrovial Activity of Atazanavir (BMS-232632) |
Mon, Jan 21, 2008 - 14:04 EST |
| ICAAC_2002_Abs_1020.pdf |
Tue, Oct 28, 2003 - 12:47 EST |
The Application of Monte Carlo Simulation to the Estimation of Susceptibility Breakpoints |
Mon, Jan 21, 2008 - 14:04 EST |
| Icaac_noncomp_v4_2005sep06_sent.pdf |
Fri, Jan 20, 2006 - 14:09 EST |
Noncompartmental Pharmacokinetics of Tigecycline in Phase 3 Studies of Patients with Complicated Skin and Skin-Structure and Intra-Abdominal Infections |
Mon, Jan 21, 2008 - 14:05 EST |
| ICAAC_TAR_Ecoli_092005_3.pdf |
Fri, Jan 20, 2006 - 14:01 EST |
Estimation of In VitroSusceptibility Breakpoints for Tigecycline Against Enterobacteriaceae |
Mon, May 5, 2008 - 11:10 EDT |
| ICAAC_TAR_Staph_091305_2.pdf |
Fri, Jan 20, 2006 - 13:54 EST |
Estimation of In VitroSusceptibility Breakpoints for Tigecycline Against Staphylococcus aureus |
Mon, May 5, 2008 - 11:10 EDT |
| ICAAC_tig_pkpd_ia_13sep2005_1.pdf |
Fri, Jan 20, 2006 - 13:44 EST |
Exposure-Response Analysis of the Efficacy of Tigecycline in Patients with Complicated Intra-Abdominal Infections (cIAI) |
Mon, May 5, 2008 - 11:10 EDT |
| IDSA-2003oct13.pdf |
Wed, Oct 22, 2003 - 10:29 EDT |
Antimicrobial Surveillance Programs: Can these Databases be Helping in Identifying Relationships Predictive of Resistance and be Applied to Patient Care? |
Mon, Jan 21, 2008 - 14:05 EST |
| IDSA_PK-PD_in_Otitis_Media_in2000_v1_2002oct23.pdf |
Mon, Apr 19, 2004 - 10:29 EDT |
Pharmacokinetics/Pharmacodynamics in Otitis Media: Comparison of Time-Dependent Antibiotics in Middle Ear Fluid |
Mon, Jan 21, 2008 - 14:04 EST |
| IDSA_Sinusitis_MEF_Poster_2003oct01.pdf |
Thu, Nov 6, 2008 - 12:49 EST |
Gatifloxacin Exposure in Maxillary Sinus and Middle Ear – All Sites of Infection Are Not Created Equal |
Thu, Nov 6, 2008 - 13:17 EST |
| IDSA_v4_2005nov02.pdf |
Thu, Sep 29, 2005 - 14:31 EDT |
Pharmacokinetic/Pharmacodynamic Model for the Safety of Tigecycline in Patients with Complicated Skin and Skin-Structure Infections |
Mon, Jan 21, 2008 - 14:05 EST |
| jb282.pdf |
Wed, Apr 30, 2003 - 10:11 EDT |
Time Course Distributions of Laboratory Indices: A strategy for Evaluating Laboratory Data from Clinical Trials |
Mon, Jan 21, 2008 - 14:04 EST |
| jb500.pdf |
Wed, Apr 30, 2003 - 10:12 EDT |
Population Pharmacokinetics (PK) of Linezolid in Patients with Community-Acquired Pneumonia (CAP) and Skin and Soft Tissue (SST) Infections |
Mon, Jan 21, 2008 - 14:04 EST |
| Meagher ECCMID 2004 PK in Renal Impairment final poster.pdf |
Wed, May 12, 2004 - 09:53 EDT |
Pharmacokinetics (PK) of Tigecycline (TG) in Healthy Adult Volunteers and in Subjects with Renal Impairment |
Mon, Jan 21, 2008 - 14:05 EST |
| monteposter.v2.pdf |
Thu, May 27, 2004 - 11:18 EDT |
Influence of Dose Size on Dose Response Relationships for Linezolid Efficacy Using Monte Carlo Simulations |
Mon, Jan 21, 2008 - 14:04 EST |
| Moxi SA BP Poster_ICAAC 2004.pdf |
Wed, Oct 27, 2004 - 10:58 EDT |
Monte Carlo Simulation to Estimate in VITRO susceptibility breakpoints for Moxifloxacin, Gatifloxacin, and Levofloxacin against Staphylococcus Aureus |
Mon, Jan 21, 2008 - 14:05 EST |
| nonmem-npem-aaps2003_2003oct22.pdf |
Wed, Oct 29, 2003 - 09:04 EST |
Comparison of Parametric (NONMEM) and Non-Parametric (NPEM) Methods for Population Pharmacokinetic (PK) Modeling of Bi-Model Populations |
Mon, Jan 21, 2008 - 14:04 EST |
| P901.ECCMID.2005mar23-final.pdf |
Wed, Mar 23, 2005 - 12:42 EST |
Pharmacodynamic Characterization of NVP-LMB415 against Haemophilus influenzae in an In Vitro Hollow-Fiber System |
Mon, Jan 21, 2008 - 14:05 EST |
| PAGE_poster_Ted_2007may31.pdf |
Tue, Jul 31, 2007 - 11:24 EDT |
The Application of Systematic Analysis for Identifying and Addressing the Needs of the Pharmacometric Process |
Mon, Jan 21, 2008 - 14:05 EST |
| phaseIIpd-slides-V3.00.09.18.pdf |
Tue, May 27, 2003 - 10:02 EDT |
Population Pharmacodynamic (PD) Assessment of Linezolid Efficacy in Community Acquired Pneumonia, Skin and Soft Tissue Infections, and Bacteremia |
Mon, May 5, 2008 - 11:09 EDT |
| pkpd_poster_2001oct11.pdf |
Wed, Apr 30, 2003 - 10:19 EDT |
Population Pharmacokinetics/Pharmacodynamics (PK/PD) of Antidepressant R, R(-) and S, S(+) Reboxetine (RBX) |
Mon, Jan 21, 2008 - 14:04 EST |
| poster.v1.2002OCT09.pdf |
Wed, Jul 9, 2003 - 14:02 EDT |
Comparison of Post-Operative Nosocomial Infection Associated with Blood Management Techniques in Cardiovascular and Orthopedic Surgery |
Mon, Jan 21, 2008 - 14:04 EST |
| poster_bridgingPK_Mar2002_v2_132_.pdf |
Wed, Apr 30, 2003 - 10:21 EDT |
Comparison of Linezolid Pharmacokinetics (PK) from Phase I Studies of Japanese and Caucasians |
Mon, Jan 21, 2008 - 14:04 EST |
| Poster_Chris_Rubino_v2_97_2.pdf |
Wed, Apr 30, 2003 - 10:22 EDT |
A New Paradigm in Pediatric Drug Development: The Application of Cognitive Engineering |
Mon, Jan 21, 2008 - 14:04 EST |
| Poster_Darcy_Foit_97.pdf |
Wed, Apr 30, 2003 - 10:28 EDT |
Transcend Global and Corporate Boundaries During Drug Development |
Mon, Jan 21, 2008 - 14:04 EST |
| Poster_Exendin_2002mar19.pdf |
Wed, Apr 30, 2003 - 10:29 EDT |
Population Modeling to Guide Phase 3 Dose Selection for AC2993 (Synthetic Exendin-4) |
Mon, Jan 21, 2008 - 14:04 EST |
| Poster_IARS_2004mar18.pdf |
Tue, Apr 6, 2004 - 14:30 EDT |
The Impact of Mivacurium and Rocuronium on Recovery Times in Ambulatory Anesthesia Procedures |
Mon, Jan 21, 2008 - 14:05 EST |
| poster_lzd_2002mar11_133_.pdf |
Wed, Apr 30, 2003 - 10:31 EDT |
Comparison of Laboratory Safety Data from Japanese and Non-Japanese in Linezoliid Phase I Studies |
Mon, Jan 21, 2008 - 14:04 EST |
| Poster_MaryEileen_McPhee_v2_97_2.pdf |
Wed, Apr 30, 2003 - 10:33 EDT |
Integrating Real-Time Data Assembly (RTDA) and Population Pharmacokintics as Tactical Components of Cognitive Engineering |
Mon, Jan 21, 2008 - 14:04 EST |
| Rel_Btwn_Levofloxacin_poster_2003sep10.pdf |
Wed, Sep 17, 2003 - 15:23 EDT |
Relationship Between Increased Levofloxacin Use and Decreased Susceptibility of Streptococcus pneumoniae : Report From the ARREST Program |
Mon, Jan 21, 2008 - 14:05 EST |
| rtda-ascpt2003-poster-2003mar28.pdf |
Wed, Apr 30, 2003 - 10:34 EDT |
Application of Real-Time Data Assembly (RTDA) to a Pivotal Phase III Pediatric Trial: A Proactive Approach to Population Pharmacokinetic/Pharmacodynamic (PK/PD) Dataset Creation |
Mon, Jan 21, 2008 - 14:04 EST |
| SABM2004.poster.v1.2004sep02.pdf |
Mon, Sep 13, 2004 - 09:48 EDT |
Postoperative Infection Rate Following Cardiac Surgery with Allogeneic vs. other Blood Management Techniques |
Mon, Jan 21, 2008 - 14:05 EST |
| scotland.poster.V3.pdf |
Wed, Nov 14, 2001 - 15:52 EST |
Efficacy of Bupropion SR on Reducing Craving in Smoking Cessation |
Mon, Jan 21, 2008 - 14:04 EST |
| scott-ecpag2002.pdf |
Tue, Jul 8, 2003 - 14:23 EDT |
Diagnosing Problems with Ka Estimation Due to Sparse Sampling |
Mon, Jan 21, 2008 - 14:04 EST |
| Sinusitis_Poster.2003sep02.pdf |
Tue, Oct 14, 2003 - 08:54 EDT |
Serial Sinus Aspirate Sampling (SSAS): A Novel Technique for Evaluating Antimicrobial Therapy of Acute Maxillary Sinusitis (AMS) |
Mon, Jan 21, 2008 - 14:05 EST |
| SMBhavnani.ARREST.S.pneumoniae_levo.IDSA2002.poster.pdf |
Tue, May 27, 2003 - 10:32 EDT |
Relationships Between Susceptibility of Streptococcus pneumoniae against Levofloxacin & Hospital- & Patient-Specific Variables: Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program) |
Mon, Jan 21, 2008 - 14:04 EST |
| SMBhavnani.P1035.Enterobacter.ECCMID.2003.pdf |
Sat, May 24, 2003 - 18:54 EDT |
Relationships Between Susceptibility of Enterobacter spp. and Hospital- and Patient-Specific Variables: Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program) |
Mon, Jan 21, 2008 - 14:05 EST |
| SMBhavnani.P1036.S.pneumoniae.ECCMID.2003.pdf |
Sat, May 24, 2003 - 18:58 EDT |
Relationships Between Susceptibility of Streptococcus pneumoniae and Hospital- and Patient-Specific Variables: Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program) |
Mon, Jan 21, 2008 - 14:05 EST |
| SMBhavnani.P1037.P.aeruginosa.ECCMID.2003.pdf |
Sat, May 24, 2003 - 19:18 EDT |
Relationships Between Susceptibility of Pseudomonas aeruginosa and Hospital- and Patient-Specific Variables: Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program) |
Mon, Jan 21, 2008 - 14:05 EST |
| tgrasel1_20_.pdf |
Thu, May 27, 2004 - 13:45 EDT |
Integration of Pharmaceutical Product Development in Asia/Japan Into the Global Program |
Mon, Jan 21, 2008 - 14:04 EST |
| tgrasel2.pdf |
Wed, Apr 30, 2003 - 10:40 EDT |
The Role of Population PK/PD Analysis During the Implementation of a Bridging Strategy for Linezolid |
Mon, Jan 21, 2008 - 14:04 EST |
| tgrasel3_22_.pdf |
Thu, May 27, 2004 - 13:48 EDT |
Internet Based Communication Strategies to Support Linezolid Bridging Programs During Global Drug Development |
Mon, Jan 21, 2008 - 14:04 EST |
| Uniqueness_Mar2002.pdf |
Wed, Jun 5, 2002 - 14:42 EDT |
Uniqueness of Solutions to Compartmental Models of Population Pharmacokinetics for Drugs Ungergoing Complex Metabolism |
Mon, Jan 21, 2008 - 14:04 EST |